Also included in net revenues was other income of $76623000 which includes a 2.6% increase to $49572000 in earnings contribution from the Benicar(R)* ...
... yen from 78.35 billion yen, thanks to cost cutting and growing sales of Daiichi Sankyo's blood-pressure drug Benicar and antibacterial agent Cravit. ...
... in the current year as a weaker yen and stronger demand in Europe for its blood pressure drug Benicar buffer earnings from slumping domestic sales. ...
ORLANDO, Fla., Nov. 7 -- Researchers have reported a possible explanation for lower rates of blood pressure control in Mexican Americans, ...
Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante sas, subsidiary of Merck kgaa, Darmstadt, ...
The arbs included were candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan medoxomil (Benicar), ...
The Japanese drug maker, which is gearing up for a major US expansion, has been benefiting from robust US sales of its high blood pressure medicine Benicar ...
all 8 news articles
*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante sas, subsidiary of Merck KGaA, Darmstadt, ...
Also included in net revenues was other income of $76623000 which includes a 2.6% increase to $49572000 in earnings contribution from the Benicar? ...